What's in BeyondBio Inc.'s pipeline?

BeyondBio Inc. has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with BeyondBio Inc.'s portfolio?

Top competitors by shared drug class: Addpharma Inc., Aevi Genomic Medicine, LLC, a Cerecor company, Ahn-Gook Pharmaceuticals Co.,Ltd, Amorphical Ltd., Angitia Incorporated Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/beyondbio-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

BeyondBio Inc. — Portfolio Competitive Intelligence Brief

BeyondBio Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Addpharma Inc. · 1 shared drug class
Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Amorphical Ltd. · 1 shared drug class
Angitia Incorporated Limited · 1 shared drug class
Applied Biology, Inc. · 1 shared drug class
Aptarion Biotech AG · 1 shared drug class
AB Science · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BeyondBio Inc.:

Cite this brief

Drug Landscape (2026). BeyondBio Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beyondbio-inc. Accessed 2026-05-14.